MediPrint Ophthalmics Completes Phase 2b Study of Drug-Eluting Contact Lens for Glaucoma

MediPrint Ophthalmics announced it has completed its SIGHT-2 phase 2b study evaluating its lead candidate (LL-BMT1) versus a control group on bimatoprost 0.01% ophthalmic solution. LL-BMT1 is a novel, preservative-free, weekly drug-eluting contact lens leveraging company’s proprietary 3D printing technology. 

The Phase 2b trial was an active-controlled, randomized, dose-finding, multicenter study evaluating the safety and efficacy of LL-BMT-1 in 28 patients diagnosed with open-angle glaucoma for 3 weeks. Both groups achieved sustained reduction of about 30% from the baseline IOP which is comparable to the reported literatures of Lumigan 0.01% eye drops. There were no serious treatment emergent adverse events reported and the lenses were well tolerated. An evaluation of dry eye and end of the day comfort for contact lens carried out per CLDEQ-8 questionnaire also showed significant improvements in dry eye and contact lens comfort.

"We are pleased with the Phase 2b results showing that our innovative bimatoprost eluting contact lens that also releases the lubricant HA simultaneously not only achieves significant sustained IOP reduction but does so with the promise of enhanced patient comfort, compliance and convenience," Houman Hemmati, MD, PhD, member of the Scientific Advisory Board at MediPrint Ophthalmics, said in a company news release. "This marks a significant leap forward in glaucoma management with contact lenses."

The company has developed a scalable manufacturing process at its facility in San Diego and plans to approach the FDA with the end-of-phase 2 meeting and progress this product to phase 3. The company looks to share the details of the data at the upcoming meetings.